FDA announces intention to comprehensively regulate lab-developed tests
The FDA announced July 31, 2014 that it intends to issue a draft guidance soon that would require moderate- and high-risk diagnostics to obtain 510(k) or premarket approval, regardless of their place of origin, putting an end to a battle to regulate laboratory-developed tests (LDTs) that’s been waged for several years. The planned draft guidance on the regulatory oversight of LDTs ,had been held up by the White House Office of Management and Budget since 2010.